Nice | Tolvaptan for treating autosomal polycystic kidney disease

This is a new guideline from NICE advising that tolvaptan can be used for treating autosomal polycystic kidney disease. It is a selective vasopressin antagonist which can reduce cell proliferation, cyst formation and fluid excretion. This reduces kidney growth and protects renal function.

Patients need to have:

  • CKD 2 or 3
  • Rapidly progressing disease

It has several side-effects, including polyuria, nocturia and frequency of urination. It can also be hepatotoxic and can elevate liver function tests.

MIMS Learning | Chronic kidney disease: clinical review

No Comments Yet.

Leave your comments